CoreCap Advisors’s Generation Bio GBIO Stock Holding History

CoreCap Advisors’s Portfolio GBIO Stock Details GBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-95	Closed	-$383	–	2936
2025 Q1	$383	Buy	95 +53	+126%	+$372	﹤0.01%	2764
2024 Q4	$440	Buy	+42	New	+$749	﹤0.01%	2562

Other funds holding GBIO

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

CoreCap Advisors's GBIO Position: Q2 2025 in Review

CoreCap Advisors sold out of Generation Bio (GBIO) in Q2 2025, closing a stake of 95 shares — an estimated $383 sold.

CoreCap Advisors first reported a position in GBIO in Q4 2024 and held it in 2 quarters. The position peaked at $440 in Q4 2024. 61 funds tracked by Wall St. Rank hold GBIO as of Q2 2025.

CoreCap Advisors reported no remaining Generation Bio position as of Q2 2025 after selling out during the quarter.
CoreCap Advisors sold 95 Generation Bio shares in Q2 2025, an estimated $383.
CoreCap Advisors first reported a position in Generation Bio in Q4 2024 and held it in 2 quarters.
CoreCap Advisors's Generation Bio position peaked at $440 in Q4 2024.
61 funds tracked by Wall St. Rank held Generation Bio as of Q2 2025.

Based on CoreCap Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.